The Asia Pacific Gastric Cancer Market would witness market growth of 18.1% CAGR during the forecast period (2023-2029).
Rapid regulatory authority approval of treatments for gastric cancer may offer the market for these drugs tremendous growth potential. In addition, the creation of new medications and treatments is greatly aided by research & development activities. Rapid improvements in cutting-edge diagnostic equipment may lead to an increase in the use of gastric cancer medications. As a result, the market for gastric cancer will have tremendous growth prospects as people become more aware of the signs and causes of gastric cancer. Additionally, prospective pipeline candidates will significantly accelerate the market's growth rate for medications that treat gastric cancer.
One of the main factors influencing the gastric cancer market is the ageing population. As the population ages, the need for therapies for gastric cancer is anticipated to rise. As people live longer, their risk of having gastric cancer rises. Gastric cancer is the sixth most frequent cancer worldwide and is more common in males than women, as reported by the World Health Organization. The prognosis for people with gastric cancer can be significantly improved by early detection and therapy. Other factors anticipated to drive the gastric cancer market include improvements in diagnosis and treatment and growth in healthcare spending.
Chemotherapy is the most popular treatment choice in nations like China, but a robust product pipeline and the anticipated approval of the treatments will support regional growth throughout the forecast period. The stage or phase of cancer at the time of diagnosis significantly impacts the likelihood of survival for stomach cancer. The survival rate increases with earlier illness development stages. In Asia Pacific, geriatric people make up the majority of the cases that are discovered at a later stage of the disease. An increase in stomach cancer cases directly correlates with the region's aging population growth. Over the projection period, the market for gastric cancer therapies will develop due to this aspect and the rising health awareness-driven desire for early detection.
The China market dominated the Asia Pacific Gastric Cancer Market by Country in 2022, and would continue to be a dominant market till 2029; thereby, achieving a market value of $761.1 million by 2029. The Japan market is experiencing a CAGR of 17.3% during (2023 - 2029). Additionally, The India market would display a CAGR of 18.9% during (2023 - 2029).
Based on Route of Administration, the market is segmented into Injectable and Oral. Based on Treatment Type, the market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy, and Radiation Therapy & Surgery. Based on Disease Type, the market is segmented into Adenocarcinoma, Carcinoid Tumor, Gastrointestinal Stromal Tumor, Lymphoma and Others. Based on Distribution Channel, the market is segmented into Specialty & Retail Pharmacies, Hospital Pharmacies, and Others. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors, HER2 Antagonists, VEGFR2 Antagonists and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Gastric Cancer Market is Projected to reach USD 6.9 Billion by 2029, at a CAGR of 17.6%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novartis AG, Pfizer, Inc., Viatris, Inc. (Mylan N.V.), F. Hoffmann-La Roche Ltd., Eli Lilly And Company, Merck & Co., Inc., Teva Pharmaceuticals Industries Ltd., Bristol Myers Squibb Company, Celltrion Healthcare Co., Ltd., and Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.).
Scope of the Study
Market Segments Covered in the Report:
By Route of Administration
By Treatment Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy & Surgery
By Disease Type
- Adenocarcinoma
- Carcinoid Tumor
- Gastrointestinal Stromal Tumor
- Lymphoma
- Others
By Distribution Channel
- Specialty & Retail Pharmacies
- Hospital Pharmacies
- Others
By Drug Class
- PD-1/PD-L1 Inhibitors
- HER2 Antagonists
- VEGFR2 Antagonists
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Novartis AG
- Pfizer, Inc.
- Viatris, Inc. (Mylan N.V.)
- F. Hoffmann-La Roche Ltd.
- Eli Lilly And Company
- Merck & Co., Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bristol Myers Squibb Company
- Celltrion Healthcare Co., Ltd.
- Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Asia Pacific Gastric Cancer Market, by Route of Administration
1.4.2 Asia Pacific Gastric Cancer Market, by Treatment Type
1.4.3 Asia Pacific Gastric Cancer Market, by Disease Type
1.4.4 Asia Pacific Gastric Cancer Market, by Distribution Channel
1.4.5 Asia Pacific Gastric Cancer Market, by Drug Class
1.4.6 Asia Pacific Gastric Cancer Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Product Launches and Product Expansions
3.2.3 Approvals & Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
Chapter 4. Asia Pacific Gastric Cancer Market by Route of Administration
4.1 Asia Pacific Injectable Market by Country
4.2 Asia Pacific Oral Market by Country
Chapter 5. Asia Pacific Gastric Cancer Market by Treatment Type
5.1 Asia Pacific Chemotherapy Market by Country
5.2 Asia Pacific Targeted Therapy Market by Country
5.3 Asia Pacific Immunotherapy Market by Country
5.4 Asia Pacific Radiation Therapy & Surgery Market by Country
Chapter 6. Asia Pacific Gastric Cancer Market by Disease Type
6.1 Asia Pacific Adenocarcinoma Market by Country
6.2 Asia Pacific Carcinoid Tumor Market by Country
6.3 Asia Pacific Gastrointestinal Stromal Tumor Market by Country
6.4 Asia Pacific Lymphoma Market by Country
6.5 Asia Pacific Others Market by Country
Chapter 7. Asia Pacific Gastric Cancer Market by Distribution Channel
7.1 Asia Pacific Specialty & Retail Pharmacies Market by Country
7.2 Asia Pacific Hospital Pharmacies Market by Country
7.3 Asia Pacific Others Market by Country
Chapter 8. Asia Pacific Gastric Cancer Market by Drug Class
8.1 Asia Pacific PD-1/PD-L1 Inhibitors Market by Country
8.2 Asia Pacific HER2 Antagonists Market by Country
8.3 Asia Pacific VEGFR2 Antagonists Market by Country
8.4 Asia Pacific Others Market by Country
Chapter 9. Asia Pacific Gastric Cancer Market by Country
9.1 China Gastric Cancer Market
9.1.1 China Gastric Cancer Market by Route of Administration
9.1.2 China Gastric Cancer Market by Treatment Type
9.1.3 China Gastric Cancer Market by Disease Type
9.1.4 China Gastric Cancer Market by Distribution Channel
9.1.5 China Gastric Cancer Market by Drug Class
9.2 Japan Gastric Cancer Market
9.2.1 Japan Gastric Cancer Market by Route of Administration
9.2.2 Japan Gastric Cancer Market by Treatment Type
9.2.3 Japan Gastric Cancer Market by Disease Type
9.2.4 Japan Gastric Cancer Market by Distribution Channel
9.2.5 Japan Gastric Cancer Market by Drug Class
9.3 India Gastric Cancer Market
9.3.1 India Gastric Cancer Market by Route of Administration
9.3.2 India Gastric Cancer Market by Treatment Type
9.3.3 India Gastric Cancer Market by Disease Type
9.3.4 India Gastric Cancer Market by Distribution Channel
9.3.5 India Gastric Cancer Market by Drug Class
9.4 South Korea Gastric Cancer Market
9.4.1 South Korea Gastric Cancer Market by Route of Administration
9.4.2 South Korea Gastric Cancer Market by Treatment Type
9.4.3 South Korea Gastric Cancer Market by Disease Type
9.4.4 South Korea Gastric Cancer Market by Distribution Channel
9.4.5 South Korea Gastric Cancer Market by Drug Class
9.5 Singapore Gastric Cancer Market
9.5.1 Singapore Gastric Cancer Market by Route of Administration
9.5.2 Singapore Gastric Cancer Market by Treatment Type
9.5.3 Singapore Gastric Cancer Market by Disease Type
9.5.4 Singapore Gastric Cancer Market by Distribution Channel
9.5.5 Singapore Gastric Cancer Market by Drug Class
9.6 Malaysia Gastric Cancer Market
9.6.1 Malaysia Gastric Cancer Market by Route of Administration
9.6.2 Malaysia Gastric Cancer Market by Treatment Type
9.6.3 Malaysia Gastric Cancer Market by Disease Type
9.6.4 Malaysia Gastric Cancer Market by Distribution Channel
9.6.5 Malaysia Gastric Cancer Market by Drug Class
9.7 Rest of Asia Pacific Gastric Cancer Market
9.7.1 Rest of Asia Pacific Gastric Cancer Market by Route of Administration
9.7.2 Rest of Asia Pacific Gastric Cancer Market by Treatment Type
9.7.3 Rest of Asia Pacific Gastric Cancer Market by Disease Type
9.7.4 Rest of Asia Pacific Gastric Cancer Market by Distribution Channel
9.7.5 Rest of Asia Pacific Gastric Cancer Market by Drug Class
Chapter 10. Company Profiles
10.1 Novartis AG
10.1.1 Company Overview
10.1.2 Financial Analysis
10.1.3 Segmental and Regional Analysis
10.1.4 Research & Development Expense
10.1.5 Recent strategies and developments:
10.1.5.1 Partnerships, Collaborations, and Agreements:
10.2 Pfizer, Inc.
10.2.1 Company Overview
10.2.2 Financial Analysis
10.2.3 Regional & Segmental Analysis
10.2.4 Research & Development Expense
10.2.5 Recent strategies and developments:
10.2.5.1 Partnerships, Collaborations, and Agreements:
10.3 Viatris, Inc. (Mylan N.V.)
10.3.1 Company Overview
10.3.2 Financial Analysis
10.3.3 Segmental Analysis
10.3.4 Research & Development Expense
10.3.5 Recent strategies and developments:
10.3.5.1 Product Launches and Product Expansions:
10.3.5.2 Approvals & Trials:
10.4 F. Hoffmann-La Roche Ltd.
10.4.1 Company Overview
10.4.2 Financial Analysis
10.4.3 Segmental and Regional Analysis
10.4.4 Research & Development Expense
10.4.5 Recent strategies and developments:
10.4.5.1 Partnerships, Collaborations, and Agreements:
10.4.5.2 Product Launches and Product Expansions:
10.5 Eli Lilly And Company
10.5.1 Company Overview
10.5.2 Financial Analysis
10.5.3 Regional Analysis
10.5.4 Research & Development Expenses
10.5.5 Recent strategies and developments:
10.5.5.1 Approvals & Trials:
10.5.5.2 Partnerships, Collaborations, and Agreements:
10.6 Merck & Co., Inc.
10.6.1 Company Overview
10.6.2 Financial Analysis
10.6.3 Segmental and Regional Analysis
10.6.4 Research & Development Expenses
10.6.5 Recent strategies and developments:
10.6.5.1 Partnerships, Collaborations, and Agreements:
10.7 Teva Pharmaceutical Industries Ltd.
10.7.1 Company Overview
10.7.2 Financial Analysis
10.7.3 Regional Analysis
10.7.4 Research & Development Expenses
10.7.5 Recent strategies and developments:
10.7.5.1 Product Launches and Product Expansions:
10.7.5.2 Approvals & Trials:
10.7.5.3 Partnerships, Collaborations, and Agreements:
10.8 Bristol Myers Squibb Company
10.8.1 Company Overview
10.8.2 Financial Analysis
10.8.3 Regional Analysis
10.8.4 Research & Development Expenses
10.8.5 Recent strategies and developments:
10.8.5.1 Partnerships, Collaborations, and Agreements:
10.8.5.2 Approvals & Trials:
10.9 Celltrion Healthcare Co., Ltd.
10.9.1 Company Overview
10.9.2 Financial Analysis
10.9.3 Recent strategies and developments:
10.9.3.1 Partnerships, Collaborations, and Agreements:
10.10. Samsung Biologics Co., Ltd. (Samsung Bioepis Co., Ltd.)
10.10.1 Company Overview
10.10.2 Financial Analysis
10.10.3 Segmental and Regional Analysis
10.10.4 Research & Development Expenses
10.10.5 Recent strategies and developments:
10.10.5.1 Approvals & Trials:
10.10.5.2 Product Launches and Product Expansions:
TABLE 1 Asia Pacific Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 2 Asia Pacific Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 3 Partnerships, Collaborations and Agreements– Gastric Cancer Market
TABLE 4 Product Launches And Product Expansions– Gastric Cancer Market
TABLE 5 Approvals & Trials – Gastric Cancer Market
TABLE 6 Asia Pacific Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 7 Asia Pacific Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 8 Asia Pacific Injectable Market by Country, 2019 - 2022, USD Million
TABLE 9 Asia Pacific Injectable Market by Country, 2023 - 2029, USD Million
TABLE 10 Asia Pacific Oral Market by Country, 2019 - 2022, USD Million
TABLE 11 Asia Pacific Oral Market by Country, 2023 - 2029, USD Million
TABLE 12 Asia Pacific Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 13 Asia Pacific Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 14 Asia Pacific Chemotherapy Market by Country, 2019 - 2022, USD Million
TABLE 15 Asia Pacific Chemotherapy Market by Country, 2023 - 2029, USD Million
TABLE 16 Asia Pacific Targeted Therapy Market by Country, 2019 - 2022, USD Million
TABLE 17 Asia Pacific Targeted Therapy Market by Country, 2023 - 2029, USD Million
TABLE 18 Asia Pacific Immunotherapy Market by Country, 2019 - 2022, USD Million
TABLE 19 Asia Pacific Immunotherapy Market by Country, 2023 - 2029, USD Million
TABLE 20 Asia Pacific Radiation Therapy & Surgery Market by Country, 2019 - 2022, USD Million
TABLE 21 Asia Pacific Radiation Therapy & Surgery Market by Country, 2023 - 2029, USD Million
TABLE 22 Asia Pacific Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 23 Asia Pacific Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 24 Asia Pacific Adenocarcinoma Market by Country, 2019 - 2022, USD Million
TABLE 25 Asia Pacific Adenocarcinoma Market by Country, 2023 - 2029, USD Million
TABLE 26 Asia Pacific Carcinoid Tumor Market by Country, 2019 - 2022, USD Million
TABLE 27 Asia Pacific Carcinoid Tumor Market by Country, 2023 - 2029, USD Million
TABLE 28 Asia Pacific Gastrointestinal Stromal Tumor Market by Country, 2019 - 2022, USD Million
TABLE 29 Asia Pacific Gastrointestinal Stromal Tumor Market by Country, 2023 - 2029, USD Million
TABLE 30 Asia Pacific Lymphoma Market by Country, 2019 - 2022, USD Million
TABLE 31 Asia Pacific Lymphoma Market by Country, 2023 - 2029, USD Million
TABLE 32 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 33 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
TABLE 34 Asia Pacific Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 35 Asia Pacific Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 36 Asia Pacific Specialty & Retail Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 37 Asia Pacific Specialty & Retail Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 38 Asia Pacific Hospital Pharmacies Market by Country, 2019 - 2022, USD Million
TABLE 39 Asia Pacific Hospital Pharmacies Market by Country, 2023 - 2029, USD Million
TABLE 40 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 41 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
TABLE 42 Asia Pacific Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 43 Asia Pacific Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 44 Asia Pacific PD-1/PD-L1 Inhibitors Market by Country, 2019 - 2022, USD Million
TABLE 45 Asia Pacific PD-1/PD-L1 Inhibitors Market by Country, 2023 - 2029, USD Million
TABLE 46 Asia Pacific HER2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 47 Asia Pacific HER2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 48 Asia Pacific VEGFR2 Antagonists Market by Country, 2019 - 2022, USD Million
TABLE 49 Asia Pacific VEGFR2 Antagonists Market by Country, 2023 - 2029, USD Million
TABLE 50 Asia Pacific Others Market by Country, 2019 - 2022, USD Million
TABLE 51 Asia Pacific Others Market by Country, 2023 - 2029, USD Million
TABLE 52 Asia Pacific Gastric Cancer Market by Country, 2019 - 2022, USD Million
TABLE 53 Asia Pacific Gastric Cancer Market by Country, 2023 - 2029, USD Million
TABLE 54 China Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 55 China Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 56 China Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 57 China Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 58 China Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 59 China Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 60 China Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 61 China Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 62 China Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 63 China Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 64 China Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 65 China Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 66 Japan Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 67 Japan Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 68 Japan Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 69 Japan Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 70 Japan Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 71 Japan Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 72 Japan Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 73 Japan Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 74 Japan Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 75 Japan Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 76 Japan Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 77 Japan Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 78 India Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 79 India Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 80 India Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 81 India Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 82 India Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 83 India Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 84 India Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 85 India Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 86 India Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 87 India Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 88 India Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 89 India Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 90 South Korea Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 91 South Korea Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 92 South Korea Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 93 South Korea Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 94 South Korea Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 95 South Korea Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 96 South Korea Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 97 South Korea Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 98 South Korea Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 99 South Korea Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 100 South Korea Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 101 South Korea Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 102 Singapore Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 103 Singapore Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 104 Singapore Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 105 Singapore Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 106 Singapore Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 107 Singapore Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 108 Singapore Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 109 Singapore Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 110 Singapore Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 111 Singapore Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 112 Singapore Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 113 Singapore Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 114 Malaysia Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 115 Malaysia Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 116 Malaysia Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 117 Malaysia Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 118 Malaysia Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 119 Malaysia Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 120 Malaysia Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 121 Malaysia Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 122 Malaysia Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 123 Malaysia Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 124 Malaysia Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 125 Malaysia Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 126 Rest of Asia Pacific Gastric Cancer Market, 2019 - 2022, USD Million
TABLE 127 Rest of Asia Pacific Gastric Cancer Market, 2023 - 2029, USD Million
TABLE 128 Rest of Asia Pacific Gastric Cancer Market by Route of Administration, 2019 - 2022, USD Million
TABLE 129 Rest of Asia Pacific Gastric Cancer Market by Route of Administration, 2023 - 2029, USD Million
TABLE 130 Rest of Asia Pacific Gastric Cancer Market by Treatment Type, 2019 - 2022, USD Million
TABLE 131 Rest of Asia Pacific Gastric Cancer Market by Treatment Type, 2023 - 2029, USD Million
TABLE 132 Rest of Asia Pacific Gastric Cancer Market by Disease Type, 2019 - 2022, USD Million
TABLE 133 Rest of Asia Pacific Gastric Cancer Market by Disease Type, 2023 - 2029, USD Million
TABLE 134 Rest of Asia Pacific Gastric Cancer Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 135 Rest of Asia Pacific Gastric Cancer Market by Distribution Channel, 2023 - 2029, USD Million
TABLE 136 Rest of Asia Pacific Gastric Cancer Market by Drug Class, 2019 - 2022, USD Million
TABLE 137 Rest of Asia Pacific Gastric Cancer Market by Drug Class, 2023 - 2029, USD Million
TABLE 138 Key Information – Novartis AG
TABLE 139 Key Information – Pfizer, Inc.
TABLE 140 key information – Viatris, Inc.
TABLE 141 KEY INFORMATION – F. Hoffmann-La Roche Ltd.
TABLE 142 Key Information – Eli Lilly And Company
TABLE 143 KEY INFORMATION - Merck & Co., Inc.
TABLE 144 Key Information – Teva Pharmaceuticals Industries Ltd.
TABLE 145 Key Information – Bristol Myers Squibb Company
TABLE 146 Key Information – Celltrion Healthcare Co., Ltd.
TABLE 147 Key Information – Samsung Biologics Co., Ltd.
List of Figures
FIG 1 Methodology for the research
FIG 2 KBV Cardinal Matrix
FIG 3 Key Leading Strategies: Percentage Distribution (2019-2023)
FIG 4 Recent strategies and developments: Viatris, Inc.
FIG 5 Recent strategies and developments: F. Hoffmann-La Roche Ltd.
FIG 6 Recent strategies and developments: Teva Pharmaceuticals Industries Ltd.
FIG 7 Recent strategies and developments: Samsung Biologics Co., Ltd.